Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis

February 6, 2012 3:27 PM EST
Get Alerts REGN Hot Sheet
Price: $362.56 -0.23%

Rating Summary:
    21 Buy, 17 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade REGN Now!
Join SI Premium – FREE
Citi maintains a 'Neutral' on Regeneron Pharma (NASDAQ: REGN) price target of $68.

Analyst, Yaron Werber, suggested that recent channel checks indicate doctors are really considering switching to REGN's Eylea from Roche's (OTC: RHHBY) Lucentis, citing: 1) cut in price; 2) lower dosing amounts, but better potency; and 3) signs Eylea is working more effectively on certain patients.

Shares of REGN are trading near session highs, up $4.38 (+4.52%) to $101.24 (new 52-wk high). However, the stock has moved up from the mid-$30 level to over $100 in the past 52-wks.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $96.86 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities


Add Your Comment